神经元PAS结构域蛋白1和3是神经精神风险基因的主调控因子
该研究用RNA测序联合染色质免疫沉淀测序,在野生型、Npas1-/-和Npas3-/-小鼠海马中鉴定NPAS1和NPAS3直接调控的基因。结果显示这些转录因子控制包括Fmr1、Ube3a和Notch在内的神经精神功能基因,且NPAS1/3靶基因在人类精神分裂症和智力障碍中遗传负担增加。
要点
- NPAS1和NPAS3直接调控Fmr1、Ube3a及Notch等神经精神相关基因。
- NPAS1/3靶基因在人类精神分裂症和智力障碍中遗传负担增加。
- NPAS1/3是神经精神功能的主调控因子,揭示诊断不同疾病的共享分子通路。
核心结论
- NPAS1和NPAS3是神经精神功能的主调控因子,其突变的相关分子病理生理得以揭示。
研究设计与样本
- 研究使用RNA测序联合染色质免疫沉淀测序,在野生型、Npas1-/-和Npas3-/-小鼠海马中鉴定NPAS1和NPAS3直接调控的基因,并以Western blot在蛋白水平验证。
主要发现
- 这是首个体内转录组规模的NPAS1和NPAS3调控基因研究,发现这些转录因子控制一组自身也是神经精神功能主调控因子的基因。
- Fmr1(脆性X综合征)和Ube3a(Angelman综合征)受NPAS3转录调控,神经发生调节因子Notch亦受其调控,这些通路的失调在蛋白水平得到确认。
- NPAS1/3靶基因在人类精神分裂症和智力障碍中显示遗传负担增加。
临床怎么用
- 这些发现为NPAS1/3突变相关神经精神疾病的分子病理生理提供无偏倚的全景视图。
- 提示诊断上不同的神经精神疾病可能共享组合性分子通路,支持跨诊断的机制研究思路。
局限性
- 研究基于小鼠模型,人类遗传与表达数据的计算整合结果需进一步实验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: NPAS3 has been established as a robust genetic risk factor in major mental illness. In mice, loss of neuronal PAS domain protein 3 (NPAS3) impairs postnatal hippocampal neurogenesis, while loss of the related protein NPAS1 promotes it. These and other findings suggest a critical role for NPAS proteins in neuropsychiatric functioning, prompting interest in the molecular pathways under their control. METHODS: We used RNA sequencing coupled with chromatin immunoprecipitation sequencing to identify genes directly regulated by NPAS1 and NPAS3 in the hippocampus of wild-type, Npas1-/-, and Npas3-/- mice. Computational integration with human genetic and expression data revealed the disease relevance of NPAS-regulated genes and pathways. Specific findings were confirmed at the protein level by Western blot. RESULTS: This is the first in vivo, transcriptome-scale investigation of genes regulated by NPAS1 and NPAS3. These transcription factors control an ensemble of genes that are themselves also major regulators of neuropsychiatric function. Specifically, Fmr1 (fragile X syndrome) and Ube3a (Angelman syndrome) are transcriptionally regulated by NPAS3, as is the neurogenesis regulator Notch. Dysregulation of these pathways was confirmed at the protein level. Furthermore, NPAS1/3 targets show increased human genetic burden for schizophrenia and intellectual disability. CONCLUSIONS: Together, these data provide a clear, unbiased view of the full spectrum of genes regulated by NPAS1 and NPAS3 and show that these transcription factors are master regulators of neuropsychiatric function. These findings expose the molecular pathophysiology of NPAS1/3 mutations and provide a striking example of the shared, combinatorial nature of molecular pathways that underlie diagnostically distinct neuropsychiatric conditions.
引用
- Michaelson JJ, Shin MK, Koh JY, et al. Neuronal PAS Domain Proteins 1 and 3 Are Master Regulators of Neuropsychiatric Risk Genes. Biol Psychiatry. 2017. PMID: 28499489. doi:10.1016/j.biopsych.2017.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。